###begin article-title 0
Outcomes of methotrexate therapy for psoriasis and relationship to genetic polymorphisms
###end article-title 0
###begin p 1
Re-use of this article is permitted in accordance with the Creative Commons Deed, Attribution 2.5, which does not permit commercial exploitation.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 99 107 <span type="species:ncbi:9606">patients</span>
The use of methotrexate is limited by interindividual variability in response. Previous studies in patients with either rheumatoid arthritis or psoriasis suggest that genetic variation across the methotrexate metabolic pathway might enable prediction of both efficacy and toxicity of the drug.
###end p 3
###begin title 4
Objectives
###end title 4
###begin p 5
###xml 144 148 144 148 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FPGS</italic>
###xml 177 180 177 180 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GGH</italic>
###xml 220 225 220 225 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MTHFR</italic>
###xml 293 297 293 297 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ATIC</italic>
###xml 337 345 <span type="species:ncbi:9606">patients</span>
To assess if single nucleotide polymorphisms (SNPs) across four genes that are relevant to methotrexate metabolism [folypolyglutamate synthase (FPGS), gamma-glutamyl hydrolase (GGH), methylenetetrahydrofolate reductase (MTHFR) and 5-aminoimidazole-4-carboxamide ribonucleotide transformylase (ATIC)] are related to treatment outcomes in patients with psoriasis.
###end p 5
###begin title 6
Methods
###end title 6
###begin p 7
###xml 200 201 200 201 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">r</italic>
###xml 201 202 201 202 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 27 35 <span type="species:ncbi:9606">patients</span>
DNA was collected from 374 patients with psoriasis who had been treated with methotrexate. Data were available on individual outcomes to therapy, namely efficacy and toxicity. Haplotype-tagging SNPs (r2 > 0.8) for the four genes with a minor allele frequency of > 5% were selected from the HAPMAP phase II data. Genotyping was undertaken using the MassARRAY spectrometric method (Sequenom(R)).
###end p 7
###begin title 8
Results
###end title 8
###begin p 9
###xml 77 85 <span type="species:ncbi:9606">patients</span>
There were no significant associations detected between clinical outcomes in patients with psoriasis treated with methotrexate and SNPs in the four genes investigated.
###end p 9
###begin title 10
Conclusions
###end title 10
###begin p 11
###xml 156 164 <span type="species:ncbi:9606">patients</span>
Genetic variation in four key genes relevant to the intracellular metabolism of methotrexate does not appear to predict response to methotrexate therapy in patients with psoriasis.
###end p 11
###begin p 12
###xml 424 425 424 425 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b1">1</xref>
###xml 426 428 426 428 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b12">12</xref>
###xml 658 663 658 663 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MTHFR</italic>
###xml 667 674 667 674 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tbl1">Table 1</xref>
###xml 188 196 <span type="species:ncbi:9606">patients</span>
Methotrexate is a first-line systemic therapy for psoriasis; however, its use is limited by unpredictable efficacy and significant hepatotoxicity and gastrointestinal symptoms. Studies in patients with psoriasis and rheumatoid arthritis treated with methotrexate suggest that functional single nucleotide polymorphisms (SNPs) in genes relevant to methotrexate metabolism may influence both efficacy and toxicity of the drug.1-12 Such studies have focused on isolated functional polymorphisms in only a few genes relevant to methotrexate metabolism and results have been variable, especially in the most investigated gene methylenetetrahydrofolate reductase (MTHFR); (Table 1).
###end p 12
###begin p 13
###xml 130 131 130 131 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">/</bold>
###xml 212 217 212 217 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MTHFR</italic>
###xml 287 292 287 292 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 293 295 293 295 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b13">13</xref>
###xml 31 39 <span type="species:ncbi:9606">patients</span>
Summary of previous studies in patients with psoriasis and rheumatoid arthritis (RA) of two single nucleotide polymorphisms (C677T/rs1801133 and A1298C/rs1801131) in the gene methylenetetrahydrofolate reductase (MTHFR) assessing efficacy and toxicity of methotrexate (adapted from Hider et al.13)
###end p 13
###begin p 14
upward arrow, Positive association; <-->, neutral finding; downward arrow, negative association. Some studies reported only associations with specific toxicities such as abnormal liver function tests (LFT) and central nervous system (CNS) effects.
###end p 14
###begin p 15
###xml 175 179 175 179 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FPGS</italic>
###xml 208 211 208 211 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GGH</italic>
###xml 214 219 214 219 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MTHFR</italic>
###xml 287 291 287 291 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ATIC</italic>
###xml 295 301 295 301 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig01">Fig. 1</xref>
###xml 324 332 <span type="species:ncbi:9606">patients</span>
We investigated 47 haplotype-tagging and three functional SNPs in four genes coding for enzymes involved in methotrexate intracellular metabolism: folypolyglutamate synthase (FPGS); gamma-glutamyl hydrolase (GGH); MTHFR; and 5-aminoimidazole-4-carboxamide ribonucleotide transformylase (ATIC); (Fig. 1) in a large cohort of patients with psoriasis treated with methotrexate.
###end p 15
###begin p 16
###xml 1172 1173 1172 1173 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1210 1211 1210 1211 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 1418 1425 1418 1425 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">de novo</italic>
Illustration of some of the key enzymes involved in the metabolism of methotrexate (MTX). MTX is transported into the cell via the solute carrier family 19, member 1 (SLC19A1). It can be actively transported out of the cell by the ATP-binding cassette transporters including ATP-binding cassette, subfamily C (CFTR/MRP), member 1-4 (ABCC1-C4) and ATP-binding cassette, subfamily G, member 2 (ABCG2). Within the cell it undergoes polyglutamation (activation) under the enzymic control of folylpolyglutamate synthase (FPGS). This is a dynamic process where glutamate residues can be removed by gamma-glutamyl hydrolase (GGH). In the polyglutamated form MTX inhibits aminoimidazole-4-carboxamide ribonucleotide transformylase (ATIC), which probably accounts for some of its anti-inflammatory effects via an intracellular rise in adenosine. Inhibition of the folate pathway may not be as important to its mechanism of action in psoriasis, but this pathway includes the enzyme 5,10-methylenetetrahydrofolate reductase (MTHFR) which has been subject to a number of MTX pharmacogenetic studies in the past. MTHFR catalyses the conversion of 5,10-methylenetetrahydrofolate 5,10-CH2-THF to 5-methyltetrahydofolate (5-CH3-THF), which is a cosubstrate for homocysteine remethylation. The polyglutamated form of MTX also inhibits thymidylate synthase (TYMS), which converts deoxyuridylate (dUMP) to deoxythymidylate (dTMP) in the de novo pyrimidine biosynthetic pathway. Genes chosen for this investigation are highlighted in red.
###end p 16
###begin title 17
Methods
###end title 17
###begin p 18
This study adheres to the declaration of Helsinki Guidelines and was approved by the relevant local research ethics committees. Subjects provided written, informed consent.
###end p 18
###begin p 19
###xml 6 14 <span type="species:ncbi:9606">patients</span>
Adult patients who had received methotrexate for treatment of psoriasis were recruited retrospectively from The Dermatology Centre, Salford Royal Hospital, Manchester, and St John's Institute of Dermatology, London.
###end p 19
###begin title 20
Evaluation of efficacy
###end title 20
###begin p 21
###xml 150 152 150 152 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b14">14</xref>
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
###xml 254 262 <span type="species:ncbi:9606">patients</span>
Patients were stratified as: (i) 'responders'--those with clearly documented clinical improvement, using the Psoriasis Area and Severity Index (PASI),14 i.e. > 75% reduction in PASI from the start of methotrexate therapy; and (ii) 'nonresponders'--those patients who showed no clear improvement, i.e. < 50% improvement in PASI while on therapy. In cases where the PASI score was not recorded, an explicit statement of response to therapy recorded in the clinical records was acceptable.
###end p 21
###begin title 22
Evaluation of toxicity
###end title 22
###begin p 23
The adverse effects of methotrexate were assessed by clinical records:
###end p 23
###begin title 24
Hepatotoxicity
###end title 24
###begin p 25
###xml 193 195 192 194 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;1</sup>
###xml 239 241 237 239 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;1</sup>
Alanine transaminase (ALT) three times the upper limit of normal on two consecutive outpatient visits and/or serum level of aminoterminal of type III procollagen (P3NP) elevated above 4.2 mug L-1 on three consecutive occasions or 8.0 mug L-1 on one occasion and/or liver biopsy changes consistent with methotrexate hepatotoxicity within 3 years of starting therapy.
###end p 25
###begin title 26
Gastrointestinal
###end title 26
###begin p 27
Severe nausea, vomiting or diarrhoea, which required cessation of methotrexate or the addition of an antiemetic.
###end p 27
###begin title 28
Bioinformatics
###end title 28
###begin p 29
###xml 116 117 116 117 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 122 123 122 123 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">r</italic>
###xml 123 124 123 124 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 300 305 300 305 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MTHFR</italic>
###xml 350 354 350 354 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ATIC</italic>
SNPS were located and downloaded from the public HAPMAP Phase II, October 2005 database (). Haplotype-tagging SNPs (n=47; r2 threshold of 0.8) were identified and filtered through the Haploview software omitting all markers having a minor allele frequency < 5%. Additional SNPs previously studied in MTHFR (rs1801133/677C>T and rs1801131/298A>C) and ATIC (rs2372536/347C>G) were also genotyped.
###end p 29
###begin title 30
Genotype analysis
###end title 30
###begin p 31
DNA was extracted from white blood cells using a standard phenol-chloroform extraction procedure. Fifty SNPs were genotyped using Sequenom(R) MassARRAYtrade mark (Sequenom Inc., San Diego, CA, U.S.A.) technology.
###end p 31
###begin title 32
Statistical analyses
###end title 32
###begin p 33
###xml 135 136 133 134 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 306 308 304 306 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b15">15</xref>
###xml 383 391 <span type="species:ncbi:9606">patients</span>
The statistical software package STATA v. 8.2 (StataCorp LP, College Station, TX, U.S.A.) was used to compare genotype frequencies (chi2 test for trend) in order to evaluate the association of each SNP with each defined treatment outcome. Logistic regression analysis was performed using the software PLINK15 to adjust for age of onset of psoriasis, sex, race and, in 294 of the 374 patients, the presence or absence of folic acid supplementation.
###end p 33
###begin title 34
Results
###end title 34
###begin p 35
###xml 40 41 40 41 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
###xml 274 282 <span type="species:ncbi:9606">patients</span>
###xml 303 311 <span type="species:ncbi:9606">patients</span>
Patients with chronic plaque psoriasis (n=374, males 61%, mean age of onset 24 years) treated with methotrexate were recruited into the study. Ninety-four per cent of the cohort was Caucasian and 6% either Chinese or Asian. Folic acid supplementation was being taken by 194 patients with psoriasis; 100 patients received no folate supplementation and data were unavailable on folic acid use in 80 cases.
###end p 35
###begin p 36
###xml 48 56 <span type="species:ncbi:9606">patients</span>
###xml 167 175 <span type="species:ncbi:9606">patients</span>
###xml 200 208 <span type="species:ncbi:9606">patients</span>
###xml 246 254 <span type="species:ncbi:9606">patients</span>
###xml 282 290 <span type="species:ncbi:9606">patients</span>
###xml 365 373 <span type="species:ncbi:9606">patients</span>
###xml 404 412 <span type="species:ncbi:9606">patients</span>
###xml 511 519 <span type="species:ncbi:9606">patients</span>
Analysis of treatment efficacy was based on 330 patients who had completed at least 3 months of methotrexate therapy and met the criteria for either 'responders' (250 patients) or 'nonresponders' (80 patients). Adverse events had occurred in 177 patients while on methotrexate; 189 patients had 'no adverse event'. Subgroup analysis of toxicity was recorded in 283 patients for hepatotoxicity and in 288 patients for gastrointestinal toxicity. Hepatotoxicity and gastrointestinal toxicity occurred in 65 and 79 patients, respectively.
###end p 36
###begin p 37
Data were obtained for 50 SNPs in the cohort with a genotype success rate of > 90%.
###end p 37
###begin title 38
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FPGS</italic>
###xml 9 12 9 12 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GGH</italic>
FPGS and GGH
###end title 38
###begin p 39
###xml 16 17 16 17 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 77 81 77 81 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FPGS</italic>
###xml 85 88 85 88 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GGH</italic>
###xml 259 263 259 263 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FPGS</italic>
###xml 274 275 274 275 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
No significant (P<0.05) genotypic associations were detected between SNPs in FPGS or GGH and either the efficacy or toxicity of methotrexate. After adjusting for age, sex and ethnicity the results remained nonsignificant for all SNPs other than rs10987746 in FPGS (adjusted P=0.01). No significant associations were detected upon adjustment for folic acid supplementation.
###end p 39
###begin title 40
MTHFR
###end title 40
###begin p 41
###xml 65 70 65 70 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MTHFR</italic>
###xml 275 282 275 282 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tbl2">Table 2</xref>
###xml 391 392 391 392 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
No significant genotypic associations were found between SNPs in MTHFR and either efficacy or toxicity of methotrexate before or after adjustment for age, sex, ethnicity and folic acid. Genotypic data for the previously investigated SNPs rs1801133 and rs1801131 are shown in Table 2. Combined analysis was performed for SNP rs1801133 T allele and SNP rs1801131 C allele with no significant (P>0.1) association found.
###end p 41
###begin p 42
###xml 219 224 219 224 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MTHFR</italic>
###xml 292 296 292 296 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ATIC</italic>
Genotypic associations and odds ratios (OR) for the carriage of allele 2 [with 95% confidence interval (CI)] for previously investigated single nucleotide polymorphisms in the genes methylenetetrahydrofolate reductase (MTHFR) and 5-aminoimidazole-4-carboxamide ribonucleotide transformylase (ATIC) and their association with the efficacy and toxicity of methotrexate in our psoriasis cohort
###end p 42
###begin p 43
No known function but has a borderline association with the onset of toxicity. 1, Major allele; 2, minor allele. Bold font indicates association with toxicity.
###end p 43
###begin title 44
ATIC
###end title 44
###begin p 45
###xml 68 72 68 72 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ATIC</italic>
###xml 155 156 155 156 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 198 205 198 205 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tbl2">Table 2</xref>
###xml 277 278 275 276 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 297 298 295 296 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 367 368 365 366 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">r</italic>
###xml 368 369 366 367 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 421 422 419 420 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 529 530 527 528 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 772 773 770 771 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 820 821 818 819 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
No significant genotypic associations were detected between SNPs in ATIC and the efficacy of methotrexate. However, two of the 15 SNPs were significantly (P<0.05) associated with onset of toxicity (Table 2). The most significant of these is the coding SNP rs2372536, with a chi2 test for trend of P=0.01. These two SNPs have a very high degree of correlation with an r2 of 1 and remain associated with onset of toxicity (P=0.01) after adjustment for the variables age, sex and ethnicity. A further SNP, rs4672768 was associated (P=0.01) with the onset of toxicity after adjustment for the above three variables. No associations remained after adjusting for folic acid supplementation. Following correction for the multiple statistical tests (Bonferroni correction factor, n=50) these associations became nonsignificant (P > 0.05). These SNPs were not associated with either hepatic or gastrointestinal toxicity (data not shown).
###end p 45
###begin title 46
Discussion
###end title 46
###begin p 47
###xml 40 41 40 41 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 77 81 77 81 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FPGS</italic>
###xml 83 86 83 86 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GGH</italic>
###xml 91 96 91 96 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MTHFR</italic>
###xml 195 196 195 196 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 275 279 273 277 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ATIC</italic>
###xml 421 425 419 423 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ATIC</italic>
###xml 437 441 435 439 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FPGS</italic>
###xml 637 638 635 636 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 916 921 914 919 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MTHFR</italic>
###xml 948 952 946 950 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ATIC</italic>
###xml 953 954 951 952 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b1">1</xref>
###xml 955 956 953 954 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b2">2</xref>
###xml 957 958 955 956 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b4">4</xref>
###xml 959 960 957 958 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b6">6</xref>
###xml 961 963 959 961 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b10">10</xref>
###xml 964 966 962 964 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b11">11</xref>
###xml 1101 1106 1099 1104 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MTHFR</italic>
###xml 1155 1159 1153 1157 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ATIC</italic>
###xml 145 153 <span type="species:ncbi:9606">patients</span>
###xml 854 862 <span type="species:ncbi:9606">patients</span>
In this study, we found no significant (P<0.05) associations between SNPs in FPGS, GGH and MTHFR and either methotrexate efficacy or toxicity in patients with psoriasis. Borderline associations (P>0.01 to </= 0.05) were detected between methotrexate toxicity and two SNPs in ATIC. Multivariate analysis accounting for age at onset of psoriasis, sex and ethnicity showed four borderline associations between three SNPs in ATIC and one in FPGS and methotrexate toxicity. When the Bonferroni correction was performed or when analysing the subgroups of hepatotoxicity and gastrointestinal toxicity, these associations became nonsignificant (P>0.05). Adjustment for the supplementation with folic acid revealed no associations between any SNPs and outcomes to methotrexate treatment. We were unable to replicate any of the previously reported associations in patients with rheumatoid arthritis and two functional SNPs in MTHFR and one functional SNP in ATIC.1,2,4,6,10,11 No associations were detected for carriage of combinations of previously described functionally independent risk alleles in the genes MTHFR (rs1801133 T allele and rs1801131 C allele) and ATIC (rs2372536 G allele).
###end p 47
###begin p 48
###xml 117 125 <span type="species:ncbi:9606">patients</span>
###xml 397 405 <span type="species:ncbi:9606">patients</span>
###xml 593 601 <span type="species:ncbi:9606">patients</span>
Clearly there are important limitations to the current study. Firstly, it was performed in a retrospective cohort of patients therefore not allowing a systematic, prospective and objective collection of phenotypic data. Furthermore, a diverse range of endpoints was used in studies reported in the literature which makes direct comparison difficult, particularly as the majority were performed in patients with rheumatoid arthritis. It is possible that we may have missed genetic variation across each of the genes studied which could influence response to methotrexate treatment in psoriasis patients. However, we estimate that we had 80% gene coverage of all SNPs reported on the phase II HAPMAP data.
###end p 48
###begin p 49
###xml 52 56 52 56 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FPGS</italic>
###xml 58 61 58 61 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GGH</italic>
###xml 63 68 63 68 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MTHFR</italic>
###xml 73 77 73 77 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ATIC</italic>
###xml 146 154 <span type="species:ncbi:9606">patients</span>
We conclude that genetic variation across the genes FPGS, GGH, MTHFR and ATIC is not predictive of either efficacy or toxicity of methotrexate in patients with psoriasis.
###end p 49
###begin p 50
We thank Dr Xiayi Ke for his support with statistical analysis. R.B.W. is in receipt of a Clinical Research Training Fellowship from the Medical Research Council which funded this work. R.L.S. is in receipt of a Stiefel Laboratories PhD studentship.
###end p 50
###begin title 51
References
###end title 51
###begin article-title 52
###xml 166 174 <span type="species:ncbi:9606">patients</span>
The C677T mutation in the methylenetetrahydrofolate reductase gene: a genetic risk factor for methotrexate-related elevation of liver enzymes in rheumatoid arthritis patients
###end article-title 52
###begin article-title 53
Polymorphisms in the methylenetetrahydrofolate reductase gene were associated with both the efficacy and the toxicity of methotrexate used for the treatment of rheumatoid arthritis, as evidenced by single locus and haplotype analyses
###end article-title 53
###begin article-title 54
Polymorphisms in folate, pyrimidine, and purine metabolism are associated with efficacy and toxicity of methotrexate in psoriasis
###end article-title 54
###begin article-title 55
###xml 126 131 126 131 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MTHFR</italic>
###xml 40 48 <span type="species:ncbi:9606">patients</span>
Methotrexate related adverse effects in patients with rheumatoid arthritis are associated with the A1298C polymorphism of the MTHFR gene
###end article-title 55
###begin article-title 56
Efficacy and toxicity of methotrexate in early rheumatoid arthritis are associated with single-nucleotide polymorphisms in genes coding for folate pathway enzymes
###end article-title 56
###begin article-title 57
###xml 104 112 <span type="species:ncbi:9606">patients</span>
Relationship between genetic variants in the adenosine pathway and outcome of methotrexate treatment in patients with recent-onset rheumatoid arthritis
###end article-title 57
###begin article-title 58
###xml 87 95 <span type="species:ncbi:9606">patients</span>
Preponderance of methylenetetrahydrofolate reductase C677T homozygosity among leukemia patients intolerant to methotrexate
###end article-title 58
###begin article-title 59
Pharmacogenomic and metabolic biomarkers in the folate pathway and their association with methotrexate effects during dosage escalation in rheumatoid arthritis
###end article-title 59
###begin article-title 60
###xml 131 139 <span type="species:ncbi:9606">patients</span>
Contribution of common polymorphisms in reduced folate carrier and gamma-glutamylhydrolase to methotrexate polyglutamate levels in patients with rheumatoid arthritis
###end article-title 60
###begin article-title 61
###xml 144 152 <span type="species:ncbi:9606">patients</span>
Polymorphisms in the thymidylate synthase and methylenetetrahydrofolate reductase genes and sensitivity to the low-dose methotrexate therapy in patients with rheumatoid arthritis
###end article-title 61
###begin article-title 62
Racial or ethnic differences in allele frequencies of single-nucleotide polymorphisms in the methylenetetrahydrofolate reductase gene and their influence on response to methotrexate in rheumatoid arthritis
###end article-title 62
###begin article-title 63
Risk genotypes in folate-dependent enzymes and their association with methotrexate-related side effects in rheumatoid arthritis
###end article-title 63
###begin article-title 64
The pharmacogenetics of methotrexate
###end article-title 64
###begin article-title 65
Severe psoriasis--oral therapy with a new retinoid
###end article-title 65
###begin article-title 66
PLINK: a tool set for whole-genome association and population-based linkage analyses
###end article-title 66

